Long‐term in vivo performance of silicone membrane lungs coated with novel methacryloyloxyethyl phosphorylcholine polymers: A pilot study
Artificial Organs · 2025
DOI: 10.1111/aor.14927 ↗Kurz gefasst
Fachartikel in der Zeitschrift Artificial Organs, 2025. Verfasst von Masaki Anraku und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The University of Tokyo Graduate School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Phosphorylcholine, Lung, Membranes, Artificial, Methacrylates. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
This study was designed to evaluate the long‐term durability, oxygenation, and pressure loss of newly developed, methacryloyloxyethyl phosphorylcholine (MPC)‐polymer‐coated, nonporous silicone hollow fiber‐membrane lungs in vivo using a pulmonary artery‐to‐left‐atrium paracorporeal configuration.
Methods
An extracorporeal circuit from the pulmonary artery (device inflow) to the left atrium (device outflow) was established using dedicated composite vascular grafts in three healthy female goats for the prototype lung testing.
Results
Duration of testing the prototype lungs was 52, 57, or 100 days. Averages of oxygen transfer rates (ml/min) at the beginning of the evaluation were 77.6 ± 17.5 at 1 L/min blood flow, 137.1 ± 58.0 at 2 L/min, and 188.9 ± 86.4 at 3 L/min. Consistent oxygen transfer performance was maintained throughout the experiments. Electron microscopy revealed minimal thrombus formation on the hollow fiber membranes inside the lungs. Native lungs were maintained in good condition without appreciable congestion in all three subjects.
Conclusions
The longevity of the hollow fibers documented here is a key requirement for the development of a device for long‐term respiratory support. The pulmonary artery‐to‐left‐atrial configuration established with our composite vascular grafts could maintain long‐term functionality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
- Department of Thoracic Surgery, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
- Fuji Systems Co., Ltd., Tokyo, Japan.
- Department of Bioengineering, The University of Tokyo Graduate School of Engineering, Tokyo, Japan.
- Department of Medical Bioengineering, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
- Department of Clinical Engineering, Kyorin University School of Medicine, Tokyo, Japan.
ORCID-Profile: Masaki Anraku
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
Zitieren
APA
Anraku, M., Yokoi, R., Hara, S., Nobori, Y., Nakao, K., Fukumoto, K., Ono, T., Sato, K., Watanabe, F., Isoyama, T., Oshiyama, H., Ono, M., Nakajima, J., & Takai, M. (2025). Long‐term in vivo performance of silicone membrane lungs coated with novel methacryloyloxyethyl phosphorylcholine polymers: A pilot study. Artificial Organs. https://doi.org/10.1111/aor.14927
Vancouver
Anraku M, Yokoi R, Hara S, Nobori Y, Nakao K, Fukumoto K, et al. Long‐term in vivo performance of silicone membrane lungs coated with novel methacryloyloxyethyl phosphorylcholine polymers: A pilot study. Artificial Organs. 2025. doi:10.1111/aor.14927
BibTeX
@article{Anraku2025,
author = {Anraku, Masaki and Yokoi, Ryo and Hara, Shintaro and Nobori, Yuya and Nakao, Keita and Fukumoto, Kento and Ono, Toshiya and Sato, Kazuaki and Watanabe, Fumikazu and Isoyama, Takashi and Oshiyama, Hiroaki and Ono, Minoru and Nakajima, Jun and Takai, Madoka},
title = {Long‐term in vivo performance of silicone membrane lungs coated with novel methacryloyloxyethyl phosphorylcholine polymers: A pilot study},
journal = {Artificial Organs},
year = {2025},
doi = {10.1111/aor.14927}
}
EUVIMED